EFAX aims to provide investors with a focused approach to international equity exposure. Unlike broad-based international ETFs that may hold hundreds or thousands of stocks, EFAX invests in a concentrated portfolio of just 10 companies. This strategy allows for potentially higher returns if the selected companies outperform, but it also introduces greater risk due to the lack of diversification. The fund's holdings are primarily large-cap companies based in Europe and Asia, including ASML Holding NV (2.74%), Roche Holding AG (1.62%), and AstraZeneca PLC (1.57%). This concentrated approach may appeal to investors seeking targeted exposure to specific international companies, but it is important to consider the increased volatility associated with a less diversified portfolio. EFAX's strategy is distinct from market-cap weighted international ETFs, which typically offer broader diversification across a larger number of holdings.
EFAX (EFAX) ETF Analysis
EFAX is an ETF providing exposure to a basket of international equities. With a focus on developed markets outside of North America, EFAX holds a concentrated portfolio of 10 stocks. The fund's top holdings include companies like ASML Holding NV and Roche Holding AG, reflecting a tilt towards European multinational corporations. Past performance does not guarantee future results.
EFAX (EFAX) ETF — Price, Holdings & Analysis
EFAX is an ETF providing exposure to a basket of international equities. With a focus on developed markets outside of North America, EFAX holds a concentrated portfolio of 10 stocks. The fund's top holdings include companies like ASML Holding NV and Roche Holding AG, reflecting a tilt towards European multinational corporations. Past performance does not guarantee future results.
ETF Overview
Risk Metrics
EFAX's concentrated portfolio of 10项持仓 introduces significant concentration risk. A substantial portion of the fund's assets is allocated to a small number of companies, meaning that the performance of these companies will have a disproportionate impact on the fund's overall returns. The fund's beta of 1.02 indicates that it has a slightly higher volatility than the market. Investors should also consider the potential impact of currency fluctuations on the fund's returns, as the underlying holdings are denominated in various foreign currencies. Past performance does not guarantee future results.
Top Holdings
- ASML Holding NV (ASML.AS): 2.74%
- Roche Holding AG (ROG.SW): 1.62%
- AstraZeneca PLC (AZN.L): 1.57%
- Novartis AG Registered Shares (NOVN.SW): 1.56%
- HSBC Holdings PLC (HSBA.L): 1.56%
- Nestle SA (NESN.SW): 1.36%
- Toyota Motor Corp (7203.T): 1.13%
- Siemens AG (SIE.DE): 1.07%
- Mitsubishi UFJ Financial Group Inc (8306.T): 1.06%
- SAP SE (SAP.DE): 1.02%
Dividend Yield
0.00%
Risk Metrics
- Beta: 1.02
常见问题
What is EFAX and what does it track?
EFAX is an exchange-traded fund that provides concentrated exposure to a small selection of international equities. Unlike many ETFs that track broad market indexes, EFAX holds only 10 stocks. This focused approach aims to deliver potentially higher returns by concentrating investments in a select group of companies. The fund's holdings are primarily large-cap companies based in Europe and Asia, reflecting a specific investment strategy within the international equity space. Investors should be aware that this concentrated approach can lead to higher volatility compared to more diversified international ETFs.
What is the expense ratio for EFAX?
The expense ratio for EFAX is not available in the provided data. Without the expense ratio, it's difficult to assess the cost-effectiveness of this ETF compared to its peers. Investors should research the fund's prospectus or other reliable sources to determine the expense ratio before investing. A higher expense ratio can erode returns over time, especially in passively managed ETFs. When evaluating ETFs, it is important to consider the expense ratio in conjunction with other factors such as investment strategy, risk profile, and historical performance.
What are the top holdings in EFAX?
EFAX's top holdings include ASML Holding NV (2.74%), Roche Holding AG (1.62%), and AstraZeneca PLC (1.57%). These companies represent a significant portion of the fund's total assets. The fund's concentration in these top holdings means that their individual performance will have a notable impact on the overall performance of EFAX. Investors should research these companies to understand their businesses and assess their potential for future growth.
Is EFAX a good long-term investment?
Whether EFAX is a suitable long-term investment depends on an individual investor's risk tolerance and investment objectives. The fund's concentrated portfolio of 10项持仓 introduces a higher level of risk compared to more diversified ETFs. The fund's beta of 1.02 suggests it may be slightly more volatile than the overall market. Investors should carefully consider these factors and their own investment goals before investing in EFAX. Past performance does not guarantee future results.
How does EFAX compare to similar ETFs?
EFAX distinguishes itself from similar ETFs through its highly concentrated portfolio of just 10 stocks. Most international equity ETFs hold a much larger number of companies to achieve broader diversification. This concentrated approach can lead to higher potential returns but also greater volatility. Without expense ratio information, it's difficult to compare the cost-effectiveness of EFAX to its peers. Investors should compare EFAX to other international ETFs based on factors such as investment strategy, risk profile, and historical performance.
Does EFAX pay dividends?
According to the provided data, EFAX has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders. Investors seeking income from their investments may want to consider other ETFs with higher dividend yields. However, it is important to note that dividend yields can fluctuate over time and are not guaranteed.